MarketCap
Prelude Therapeutics Incorporated PRLD
$ 3.8
0.53%
Facebook
X
Telegram
Prelude Therapeutics Incorporated Total Shareholders Equity | PRLD
Annual Total Shareholders Equity Prelude Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.6 M | 131 M | 237 M | 195 M | 286 M | 212 M | -49.4 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 286 M | -49.4 M | 154 M |
Quarterly Total Shareholders Equity Prelude Therapeutics Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 M | 60.2 M | 237 M | 58.5 M | 75.8 M | 103 M | 195 M | 156 M | 182 M | 211 M | 286 M | 238 M | 262 M | 175 M | - | 217 M | 241 M | 262 M | 286 M | 311 M | 334 M | 357 M | 212 M | 212 M | 212 M | 212 M | -49.4 M | -49.4 M | -33.3 M | -27.9 M | -22.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 357 M | -49.4 M | 168 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioAtla
BCAB
|
-36.2 M | $ 1.74 | 0.64 % | $ 102 M |  USA |
 |
Catalyst Pharmaceuticals
CPRX
|
954 M | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
-105 M | $ 26.14 | 3.24 % | $ 1.26 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
106 M | $ 14.79 | 6.25 % | $ 1.32 B | USA |
 |
ARCA biopharma
ABIO
|
472 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
63.9 M | - | 4.01 % | $ 150 M |  Canada |
 |
ADiTx Therapeutics
ADTX
|
5.61 M | - | - | $ 374 | USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
370 M | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
251 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
306 M | $ 0.36 | -10.07 % | $ 26.4 K | USA |
 |
Bio-Path Holdings
BPTH
|
154 K | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
20.9 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
76.5 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
14.9 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
6.84 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
6.84 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
18.2 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-7.58 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-9.02 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
-302 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
-74.3 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
41.1 M | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
-30 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
42 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
274 M | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
51.4 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
240 M | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
203 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-6.64 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
3.97 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
31.2 M | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
-128 M | $ 9.97 | -2.25 % | $ 1.62 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
2.67 M | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
6.15 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
460 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-2.71 M | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
155 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
70.1 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
9.66 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
493 M | - | -7.74 % | $ 41.6 M | USA |